Study Looks at Co-Use of CYP2D6-Metabolizing Opioids, Antidepressants in Seniors
By Elana Gotkine HealthDay Reporter
MONDAY, July 22, 2024 -- For older nursing home (NH) residents, use of CYP2D6-metabolized opioids concomitantly with CYP2D6-inhibiting antidepressants is associated with worsening pain and increased risk of opioid-related adverse events (ORAEs), according to a study published online July 23 in the Annals of Internal Medicine.
Yu-Jung Jenny Wei, Ph.D., from the College of Pharmacy at The Ohio State University in Columbus, and colleagues examined the associations of concomitant use of CYP2D6-metabolized opioids and antidepressants with clinical outcomes and ORAEs in a retrospective cohort study using a target trial emulation framework. Data were included for 29,435 long-term residents aged 65 years and older receiving CYP2D6-metabolized opioids with a disease indication for antidepressant use who initiated CYP2D6-inhibiting versus CYP2D6-neutral antidepressants.
The researchers found that use of CYP2D6-metabolized opioids concomitantly with CYP2D6-inhibiting antidepressants was associated with increased adjusted rate ratio of worsening pain compared with CYP2D6-neutral antidepressants (1.13). In addition, CYP2D6-inhibiting antidepressants were associated with higher adjusted incidence rate ratios of pain-related hospitalization, pain-related emergency department visits, and opioid use disorder (1.37, 1.49, and 1.93, respectively); no differences were seen in physical function, depression, and opioid overdose.
"When co-use of CYP2D6-metabolizing opioids and antidepressants is clinically needed, selecting CYP2D6-neutral antidepressants, rather than CYP2D6-inhibiting antidepressants, may provide better or equal clinical and adverse outcomes," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2024
Read this next
Psilocybin Plus Psychotherapy Offers Lasting Benefit in Cancer, Depression
MONDAY, June 16, 2025 -- For cancer patients with a major depressive disorder, a single dose of psilocybin combined with psychological support can provide sustained relief for...
Shorter Leukocyte Telomere Length Linked to Higher Incidence of Age-Related Brain Diseases
THURSDAY, June 12, 2025 -- Individuals with shorter leukocyte telomere length (LTL) have a higher incidence of stroke, dementia, and late-life depression (LLD), individually and...
Talking Therapy Reduces Depression, Anxiety Symptoms in Stroke Survivors
THURSDAY, June 12, 2025 -- For stroke survivors, talking therapy is associated with moderate reductions in depression and large reductions in anxiety symptoms, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.